TY - JOUR
T1 - Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2
AU - Klingler, JÃromine
AU - Weiss, Svenja
AU - Itri, Vincenza
AU - Liu, Xiaomei
AU - Oguntuyo, Kasopefoluwa Y.
AU - Stevens, Christian
AU - Ikegame, Satoshi
AU - Hung, Chuan Tien
AU - Enyindah-Asonye, Gospel
AU - Amanat, Fatima
AU - Baine, Ian
AU - Arinsburg, Suzanne
AU - Bandres, Juan C.
AU - Kojic, Erna Milunka
AU - Stoever, Jonathan
AU - Jurczyszak, Denise
AU - Bermudez-Gonzalez, Maria
AU - NÃidas, Arthur
AU - Liu, Sean
AU - Lee, Benhur
AU - Zolla-Pazner, Susan
AU - Hioe, Catarina E.
N1 - Publisher Copyright:
© 2020 The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected].
PY - 2021/3/15
Y1 - 2021/3/15
N2 - Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people globally. Virus infection requires the receptor-binding domain (RBD) of the spike protein. Although studies have demonstrated anti-spike and-RBD antibodies to be protective in animal models, and convalescent plasma as a promising therapeutic option, little is known about immunoglobulin isotypes capable of blocking infection. Methods: We studied spike- A nd RBD-specific immunoglobulin isotypes in convalescent and acute plasma/serum samples using a multiplex bead assay. We also determined virus neutralization activities in plasma and serum samples, and purified immunoglobulin fractions using a vesicular stomatitis pseudovirus assay. Results: Spike- A nd RBD-specific immunoglobulin (Ig) M, IgG1, and IgA1 were produced by all or nearly all subjects at variable levels and detected early after infection. All samples displayed neutralizing activity. Regression analyses revealed that IgM and IgG1 contributed most to neutralization, consistent with IgM and IgG fractions' neutralization potency. IgA also exhibited neutralizing activity, but with lower potency. Conclusion: IgG, IgM, and IgA are critical components of convalescent plasma used for treatment of coronavirus disease 2019 (COVID-19).
AB - Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people globally. Virus infection requires the receptor-binding domain (RBD) of the spike protein. Although studies have demonstrated anti-spike and-RBD antibodies to be protective in animal models, and convalescent plasma as a promising therapeutic option, little is known about immunoglobulin isotypes capable of blocking infection. Methods: We studied spike- A nd RBD-specific immunoglobulin isotypes in convalescent and acute plasma/serum samples using a multiplex bead assay. We also determined virus neutralization activities in plasma and serum samples, and purified immunoglobulin fractions using a vesicular stomatitis pseudovirus assay. Results: Spike- A nd RBD-specific immunoglobulin (Ig) M, IgG1, and IgA1 were produced by all or nearly all subjects at variable levels and detected early after infection. All samples displayed neutralizing activity. Regression analyses revealed that IgM and IgG1 contributed most to neutralization, consistent with IgM and IgG fractions' neutralization potency. IgA also exhibited neutralizing activity, but with lower potency. Conclusion: IgG, IgM, and IgA are critical components of convalescent plasma used for treatment of coronavirus disease 2019 (COVID-19).
KW - COVID-19
KW - SARS-CoV-2
KW - antibody isotypes
KW - convalescent plasma
KW - neutralization
UR - http://www.scopus.com/inward/record.url?scp=85103683954&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiaa784
DO - 10.1093/infdis/jiaa784
M3 - Article
C2 - 33367897
AN - SCOPUS:85103683954
SN - 0022-1899
VL - 223
SP - 957
EP - 970
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 6
ER -